title: Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study.
abstract: In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis.
authors.affiliation: Klinikum Leverkusen (University of Cologne), Medizin. Klinik 4, 51375 Leverkusen, Germany. ringe@klinikum-lev.de
authors.forename: J D
authors.initials: JD
authors.lastname: Ringe
authors.forename: A
authors.initials: A
authors.lastname: Dorst
authors.forename: H
authors.initials: H
authors.lastname: Faber
authors.forename: C
authors.initials: C
authors.lastname: Kipshoven
authors.forename: L C
authors.initials: LC
authors.lastname: Rovati
authors.forename: I
authors.initials: I
authors.lastname: Setnikar
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism; D002111:Calcaneus / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D002118:Calcium / Q000008:administration & dosage*; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D005459:Fluorides / Q000627:therapeutic use*; D005598:Fractures, Spontaneous / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D010146:Pain / Q000503:physiopathology / Q000517:prevention & control; D010710:Phosphates / Q000627:therapeutic use*; D010865:Pilot Projects; D016059:Range of Motion, Articular / Q000187:drug effects; D016103:Spinal Fractures / Q000000981:diagnostic imaging / Q000517:prevention & control; D016896:Treatment Outcome; D014463:Ultrasonography; D014807:Vitamin D / Q000008:administration & dosage*
chemical_list: D010710:Phosphates; D014807:Vitamin D; C012980:fluorophosphate; D012968:Etidronic Acid; D005459:Fluorides; D002118:Calcium